Franklin Biotechnology Discovery Fund Class C FBTDX

Morningstar Medalist Rating
  • NAV / 1-Day Return$165.57  /  −0.42%
  • Fund Size$1.1B
  • Adjusted Expense Ratio1.760%
  • Net Expense Ratio1.760%
  • Fee Level: DistributionBelow Average
  • Share Class TypeLevel Load
  • Morningstar CategoryHealth
  • Equity Style Box (Funds)Mid Growth
  • Minimum Initial Investment$1,000
  • Investment StatusOpen
  • TTM Yield1.48%
  • Turnover Ratio38%

Morningstar’s Analysis FBTDX

Will FBTDX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

Still not a standout despite a hot streak.

Associate Analyst Natalia  Arrigoni

Natalia Arrigoni

Associate Analyst

Summary

Franklin Biotechnology Discovery’s veteran managers and strong recent results inspire some confidence, but limited research support and an undifferentiated process limit its appeal.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTDX

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings37.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Jazz Pharmaceuticals PLC

5.0157M
Healthcare

Amgen Inc

4.7254M
Healthcare

Gilead Sciences Inc

4.4951M
Healthcare

argenx SE ADR

4.1447M
Healthcare

Vertex Pharmaceuticals Inc

3.9545M
Healthcare

Regeneron Pharmaceuticals Inc

3.8143M
Healthcare

Revolution Medicines Inc Ordinary Shares

3.3538M
Healthcare

Guardant Health Inc

3.0134M
Healthcare

AstraZeneca PLC

2.9033M
Healthcare

BridgeBio Pharma Inc

2.5229M
Healthcare

Sponsor Center